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Effect of prolonged bicarbonate administration on plasma potassium in
terminal renal failure. In hemodialysis patients with hyperkalemia, i.v.
sodium bicarbonate has recently been found to be ineffective in
lowering plasma potassium within one hour. In the present study the
effect of a prolonged bicarbonate infusion on plasma potassium was
investigated. Twelve patients with terminal renal failure who were on
hemodialysis were infused i.v. with 8.4% sodium bicarbonate (4 mmol/
mm) for one hour and with 1.4% (0.5 mmol/min) for five hours (total
amount 390 mmol). Plasma bicarbonate rose from 17.5 at baseline to
28.4 and 29.6 mmollliter, and blood pH from 7.32 to 7.46 and 7.48 at one
and six hours, respectively. Plasma potassium did not change signifi-
cantly after one and two hours (6.04 at baseline, 5.91 and 5.77
mmol/liter, respectively). Only at four and six hours did a moderate
decline to 5.44 (P < 0.05) and to 5.30 (P < 0.01) occur, of which
approximately half was calculated to be due to ECF volume expansion.
However, no change or a very moderate decrease was observed in three
patients even after six hours (+0.19, —0.32, —0.33 mmol/liter). Five
patients with higher baseline plasma potassium (6.15 to 8.15 mmol/liter)
behaved like seven with lower levels (5.25 to 5.87 mmol/liter). Tented
T-waves in the ECG of seven patients disappeared after one hour only
in one patient. Plasma aldosterone, norepinephrine and epinephnne
were normal to elevated before and tended to fall during i.v. bicarbon-
ate. Plasma dopamine and insulin were in the normal range. It is
concluded that in patients with terminal renal failure maintained on
hemodialysis and with sufficient levels of potassium regulating hor-
mones, i.v. bicarbonate was ineffective as a treatment of hyperkalemia
for up to two hours; after four and six hours it was accompanied by a
modest fall in plasma potassium which, however, was not quite reliable
and was obtained at the cost of a considerable sodium-volume load.
Patients with chronic terminal renal failure are at a high risk
for life-threatening hyperkalemia. This is the result of dimin-
ished renal potassium excretion but also of an impaired extra-
renal potassium tolerance [1—4]. The mechanisms underlying
the impaired extrarenal potassium homeostasis are not entirely
clear. Major regulating factors include acid-base changes and
hormones such as insulin, epinephrine, and aldosterone [1, 2].
Based on these interactions, various therapeutic approaches
have been recommended for the treatment of hyperkalemic
emergencies [1, 5—10]. Among them intravenous bicarbonate
still seems to be a favorite choice of many nephrologists, as
indicated in a recent survey [10]. In hemodialysis patients,
intravenous bicarbonate was previously shown to be ineffective
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in lowering plasma potassium within 60 minutes [11]. However,
the effect of this treatment was not followed over several hours.
Therefore, the present study was designed to investigate the
effects of a prolonged intravenous infusion of bicarbonate in
patients with terminal renal failure and hyperkalemia.
Methods
Patients
Twelve patients with terminal renal failure receiving mainte-
nance hemodialysis were studied. They were selected because
they repeatedly had predialysis plasma potassium levels of
 5.8 mmol/liter. There were six women and six men, aged 24
to 66 years [mean age 48.5 3.5 (sEM) years]. The renal
diagnosis was chronic glomerulonephritis in four, polycystic
kidney disease in four, analgesic nephropathy in two, and
nephrosclerosis or interstitial nephritis of unknown origin in
one each. Hemodialysis with capillary dialyzers was performed
thrice weekly using bicarbonate as a buffer in the dialysate. All
patients continued to receive their usual medication, including
phosphate binders (aluminum hydroxide or calcium salts) and,
in some cases, benzodiazepines at bedtime; four patients re-
ceived a small dose of the cardio-selective f3-blocker, atenolol
(4 times 25 mg/week), and one received nifedipine for treatment
of hypertension, but none was taking angiotensin converting
enzyme inhibitors.
Study design
The measurements were performed in the morning after an
overnight fast during the hours preceding a regularly scheduled
hemodialysis. Upon arrival of the patient, standard hemodialy-
sis fistula needles were placed. The needle close to the arterio-
venous anastomosis was used for blood sampling, the second
was used for intravenous bicarbonate infusion given with a
constant infusion pump (IVAC 531, IVAC Corporation, San
Diego, California, USA). After one hour of recumbency, basal
levels of blood gas parameters and plasma sodium, potassium,
chloride, osmolality, renin, aldosterone, catecholamines and
insulin were measured.
Thereafter, bicarbonate was infused intravenously over six
hours. During the first hour, bicarbonate 8.4% in water (without
glucose) was delivered at a rate of 4 mmol/min (except in 1 very
small and light female patient who received only 2 mmollmin)
and in a total volume of 240 ml. During the second to sixth hour,
1.4% bicarbonate in water (without glucose) was given at a rate
of 0.5 mmollmin and in a total volume of 900 ml. Consequently,
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the volume infused over the entire six-hour treatment period
amounted to 1140 ml with a total of 390 mmol of sodium.
Plasma potassium, sodium, and blood gas parameters were
measured at 30, 60, 120, 240 and 360 minutes, osmolality at 60
and 360 minutes, whereas the other determinations were re-
peated at 60, 120, 240 and 360 minutes (except in 3 patients in
whom hormone measurements were obtained only after 60 and
360 nun). At baseline and after 60 and 360 minutes a standard 12
lead electrocardiogram was recorded. The subjects remained in
a supine position throughout the procedure. They were allowed
up to 300 ml of water if thirsty, but no food. Urine was collected
by spontaneous voiding over the entire period in four subjects
with some residual diuresis for measurement of potassium
excretion; eight patients were anuric.
Analytical procedures
Plasma potassium and sodium were measured by flame
photometry, chloride was determined by mercury (II) thiocya-
nate method in a Greiner G 400 Analyzer (Langenthal, Switzer-
land). Blood pH and partial pressure of carbon dioxide were
determined immediately after withdrawal with an Instrumenta-
tion Laboratory 213 blood gas analyzer (Milan, Italy). Bicar-
bonate concentration was calculated with the Henderson-Has-
selbalch equation using a pK of 6.10 and a solubility coefficient
for carbon dioxide of 0.0301. Plasma glucose and osmolality as
well as insulin, renin activity, aldosterone and plasma catechol-
amines were determined as described previously [11].
Calculation of extracellular fluid (ECF) volume changes and
of bicarbonate space
The ECF volume participating in rapid fluid volume changes
was calculated as one third of whole body water, which was
assumed to be 60 and 50% of body weight in men and in women,
respectively [12]. Changes in ECF volume (LECF) were esti-
mated using chloride space arithmetic as follows:
IECF = eECF - iECF
eECF = (iECF X i[C1] + bci)/e[ClJe
where eECF is the experimental ECF volume, iECF the initial
ECF volume, [Cl]e is the initial extracellular chloride concen-
tration, b1 is the chloride balance (representing urinary chlo-
ride losses), and e[Cl]e is experimental extracellular chloride
concentration. Chloride space arithmetic assumes that internal
shifts of chloride do not occur.
Bicarbonate space was calculated using the formula: retained
bicarbonate in mmoL/kg body weight divided by final minus
initial plasma bicarbonate. In order to correct for volume
expansion, initial bicarbonate was multiplied by the ratio of
final over initial plasma chloride concentration (= corrected
bicarbonate space).
Statistical analysis
Statistics were performed with the help of the Statistical
Analysis System software package (version OS 6.03, SAS
Institute, Inc., Cary, North Carolina, USA). Comparison of
variations over time was by analysis of variance with Scheffe's
multiple comparison and also by paired t-test. Pearson correla-
tion analysis was used for assessment of relationships between
120 240 360
Duration of bicarbonate infusion, minutes
Fig. 1. Changes in plasma potassium (mmol/liter) during intravenous
infusion of bicarbonate. Vertical bars denote SEM. * < 0,05; tP <
0.01.
variables. Values are given as mean SEM. Since natural
logarithmic transformation rather than absolute values followed
a Gaussian distribution, the transformed values of plasma renin
activity, aldosterone, insulin, epinephrine, norepinephrine and
dopamine levels were used for statistical analysis.
The study was approved by the ethical committee of Kantons-
spital Aarau, Switzerland.
Results
Effect on plasma potassium, sodium, osmolality, glucose and
blood gas parameters
Mean basal plasma potassium was 6.04 0.23 mmol/liter
(sEM). Five patients had severe hyperkalemia with plasma
potassium levels ranging from 6.15 to 8.15 mmol/liter (mean
6.76 0.36 mmoL/liter); the other seven had moderate hyper-
kalemia of 5.25 to 5.87 mmol/liter (mean 5.53 0.10 mmoll
liter). During bicarbonate infusion, plasma potassium was un-
changed at 30 minutes (6.06 0.25 mmollliter) and 60 minutes
(5.90 0.26 mmollliter; Fig. I). At 120 minutes, plasma
potassium averaged 5.77 mmol/liter, a change that was still not
significant by ANOVA. Only 240 and 360 minutes after the start
of the intravenous bicarbonate infusion did a significant decline
in plasma potassium become evident. The five patients with a
plasma potassium above 6 mmol/liter had no greater decline at
60 and 360 minutes than the seven with a plasma potassium
below 6.0 mmol/liter (—0.01 and —0.66 vs. —0.13 and —0.77
mmol/Iiter; Fig. 2).
Plasma sodium increased significantly from 136.9 0.4 to
144.7 0.5 mmol/liter (P < 0.001) at 60 minutes of bicarbonate
infusion and remained in this range over the entire study period
(143.9 0.7 mmol/liter at 360 mm). Osmolality rose from 303
3 to 313 3 at 60 minutes and to 309 2 mOsm/liter at 360
minutes. This change was not significant by ANOVA but highly
significant by paired t-test (P < 0.001). Mean plasma glucose
remained in the normal range throughout the study period.
Plasma bicarbonate increased markedly from 17.5 0.9 to
24.2 1.0mmol/liter (P <0.001) at 30 minutes and to 28.4 1.1
mmol/liter (P < 0.0001) at 60 minutes, and remained in the latter
range thereafter. Blood pH rose in parallel from 7.31 0.01 to
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Table 1. Extracellular fluid volume changes (z ECF) and bicarbonate
space during intravenous infusion of bicarbonate
Bicarbonate space mi/kg body wt
ECF Uncorrected Corrected
ml for ECF for LECF
At 60 minutes 389 73 349 20 335 19
At 360 minutes 762 94 531 24 501 24
the fall of plasma potassium was then calculated using the ECF
figures of Table 1. It was found that the minute drop of plasma
potassium at 60 minutes could be fully accounted for by dilution
360 in all patients, except one who had an extraordinarily large fall
of plasma potassium of 0.68 mmol/liter; at 360 minutes, 50.0
6.7% of the decrease of plasma potassium was calculated to be
due to ECF volume expansion (with similar figures at 120 and
240 mm, that is, 50.2 7.3 and 54.7 7.0%, respectively).
Bicarbonate spaces increased during the experiment; they were
4 to 5% smaller when corrected for ECF volume expansion
(Table 1).
Effect of bicarbonate infusion on ECG
Basal ECG tracings revealed tented T-waves in seven pa-
tients (plasma potassium 5.25 to 8.15 mmollliter) and no signs of
hyperkalemia in the other five (plasma potassium 5.28 to 6.15
mmollliter). The patient with the highest value manifested a
pronounced S-T-elevation in lead V, (resembling acute myocar-
dial infarction). Loss of P-waves or widening of the QRS-
complex were not observed. The T-wave tenting improved or
disappeared after 60 minutes in one patient without a change in
plasma potassium (5.62 vs. 5.60 mmollliter) and after 360
minutes in two others whose plasma potassium had decreased
from 6.35 to 5.76 and from 6.40 to 6.08 mmol/liter, respectively.
In the patient with the initial plasma potassium of 8.15 mmoll
liter, S-T elevation in lead V, improved after 360 minutes when
plasma potassium had decreased to 7.30 mmol/liter.
Effects on hormones
0.0001) at 60 minutes (Fig. 3). Plasma chloride decreased from
101.9 0.8 to 98.9 1.2 mmollliter (P < 0.002) at 60 minutes
and to 96.2 1.4 mmollliter (P < 0,001) at 360 minutes.
The four patients with some residual diuresis excreted 2, 3, 9
and 10 mmol, respectively, of potassium over the entire study
period.
Correlations
Changes in plasma potassium during bicarbonate infusion did
not correlate with basal values or changes in plasma bicarbon-
ate or blood pH. This held true when the 12 hemodialysis
patients of the present study were analyzed alone or together
with nine patients from our previous study, who underwent the
same protocol for 60 minutes [ill and did not participate in the
present investigation. Similarly, no significant correlation was
found between plasma potassium or changes in plasma potas-
sium on the one hand and plasma osmolality or plasma sodium
on the other.
Based on changes in plasma chloride concentration it could
be calculated that ECF volume expanded considerably during
bicarbonate infusion. The contribution of expansion of ECF to
Mean supine plasma renin activity was elevated in compari-
son with the age related normal range under basal conditions
and was not significantly modified during bicarbonate infusion
(Table 2).
Mean supine plasma aldosterone was increased under basal
conditions and tended to decrease during the study procedure
(statistically not significant). Aldosterone correlated signifi-
cantly with corresponding plasma potassium concentrations
under basal conditions or throughout the study, (r = 0.59, P <
0.05 and r = 0.60, P < 0.001, respectively).
Plasma epinephrine and norepinephrine also were on average
increased under basal conditions and tended to decrease (sta-
tistically not significantly) during the study procedure. Plasma
dopamine and insulin were normal and unaltered during bicar-
bonate infusion.
Discussion
It is widely held that intravenous bicarbonate acutely restores
elevated plasma potassium levels in patients with renal failure.
Bicarbonate infusion is advocated in standard textbooks of
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Table 2. Plasma renin, aldosterone, insulin and catecholarnines during intravenous infusion of bicarbonate
Time mm
0 60 120 240 360
Plasma renin activity ng/,nl/h (normal 0.4—3.4)
Plasma aldosterone ng/dl (normal 2—10)
Plasma insulin mU/liter (normal 5—20)
Plasma epinephrine ng/dl (normal 2—11)
Plasma norepinephrine ng/dl (normal 10—50)































lvloreover, in a recent survey intravenous bicarbonate still
ranked second (after intravenous calcium gluconate) as the
initial treatment for hyperkalemia in a majority of 65 directors
of nephrology training programs [101. This recommendation is
based on uncontrolled clinical studies performed in the surpris-
ingly small number of a total of 17 patients with renal failure
[13—16]. However, in a recent study intravenous infusion of
bicarbonate in 13 patients with terminal renal failure undergoing
hemodialysis failed to lower plasma potassium within sixty
minutes [11]. The results of the present investigation extend this
observation and corroborate that intravenous bicarbonate is
ineffective as an emergency treatment of hyperkalemia in
patients with terminal renal failure who are on maintenance
hemodialysis.
In such patients the plasma potassium-lowering effect of
intravenous bicarbonate seems to have a very slow onset,
requiring several hours to develop. This time interval was 3.5
hours in the often cited study by Fraley and Adler [16], as
pointed out recently by us and others [11, 17]. For this reason,
the bicarbonate infusion was prolonged to six hours in the
present study. The absence of a significant improvement of
hyperkalemia after two hours and appearance of a reduction
after four hours is in agreement with an earlier study [16] and a
recent abstract describing a modest lowering of plasma potas-
sium by isotonic bicarbonate infusion after three hours [18].
However, it must be pointed out that even prolonged bicarbon-
ate application may be unreliable since in three of our 12
hemodialysis patients no or a minor fall of plasma potassium
was found even after six hours (+0.19, —0.32 and —0.33
mmol/liter, respectively; Fig. 2).
Since infusions of hypertonic mannitol or saline (but not of
hypertonic bicarbonate) have been shown to elevate plasma
potassium [19, 20], the possibility that hypertonicity might per
se antagonize a plasma potassium-lowering action of bicarbon-
ate had been investigated in our previous study [11]. It was found
that isotonic bicarbonate which did not elevate plasma osmolality
and sodium similarly failed to decrease plasma potassium. In the
present study, the lack of a correlation between plasma potassium
or change in plasma potassium on the one hand and plasma
osmolality or sodium on the other are an additional argument
against the role of hypertonicity in this respect.
It seemed to be important to assess the contribution of
expansion of ECF volume in the fall of plasma potassium. A
recent report suggested that hemodilution is negligible, because
hematocrit and osmolality did not change [18]. However, the
volume of isotonic sodium bicarbonate infused over two hours
was so small (roughly 400 ml) that no significant change was to
be expected even if the whole volume had remained in the
extracellular volume space. In our study, the amount of sodium
(390 mmol) and of total volume (1,140 ml) infused was much
larger. We examined this issue using chloride space arithmetic
and found that roughly half of the fall of plasma potassium could
be accounted for by dilution arising from expansion of ECF
space after two to six hours of bicarbonate infusion.
The situation concerning bicarbonate distribution is quite
complex [21, 22]. The bicarbonate space increased during
infusion in our study, indicating that a considerable part of the
administered bicarbonate entered the intracellular space. As-
suming that mean whole body water amounts to 55% of body
weight, the value of 501 ml/kg body weight for bicarbonate
space indicates that the buffer was almost evenly distributed in
body water from 120 minutes onward. It must be pointed out
that the usefulness of intravenous bicarbonate in acidosis of
various etiology has been seriously questioned, since physio-
logical studies indicate that this may entail dangerous paradox-
ical intracellular acidosis [23—26]. Moreover, the considerable
expansion of ECF volume induced by our protocol is of concern
especially in patients without excretory renal function. During
the infusion of 8.4% sodium bicarbonate at a high rate ECF was
expanded by about 400 ml at 60 minutes, considerably more
than the 240 ml infused. This was undoubtedly due to a shift of
water out of the cells in consequence of the induced hyperto-
nicity. The further rise of the ECF volume to a total of roughly
800 ml at 360 minutes was promptly relieved in our patients,
because hemodialysis was initiated immediately after the end of
the study. However, in a clinical situation without rapid avail-
ability of a dialysis procedure, the protocol used may impose a
substantial risk of pulmonary edema to the patient with end-
stage renal failure. Since these patients usually have fluid
overload when they develop hyperkalemia, the substantial
obligatory fluid expansion of alkali therapy in general may be
life-threatening.
The present results obviously apply only to patients with
terminal renal failure maintained on regular hemodialysis. Al-
though the mean basal plasma potassium was somewhat higher
in the patients of the present study than in our earlier study
(6.04 vs. 5.66 mmollliter), it was generally not as high as it can
be in emergencies. In the group of patients studied, those with
higher plasma potassium (6.15 to 8.15 mmol/liter) responded no
better than those with hyperkalemia of a more modest degree
(Fig. 2). Moreover, there was no correlation between the basal
plasma potassium and its change during bicarbonate infusion.
This demonstrates the lack of acute therapeutic efficacy regard-
less of the severity of hyperkalemia in patients with terminal
renal failure on maintenance hemodialysis.
The general influence of the degree of acidosis is difficult to
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evaluate from the present study. Although less cooperative
hemodialysis patients with a tendency to poor dietary compli-
ance were included, and plasma bicarbonate was lower than in
the earlier investigation (17 to 18 vs. 21 to 22 mmollliter),
extreme degrees of metabolic acidosis as seen in uremic emer-
gencies were not present. In our patients no correlation be-
tween basal blood pH or plasma bicarbonate and changes in
plasma potassium after 60 minutes were found. This held true
when the patients of our previous study were added in order to
increase sample size. Moreover, another study evaluating the
increase of plasma potassium after intravenous potassium also
failed to find a relationship with the degree of acidosis [27].
Nevertheless, it is still possible that alkali therapy for hyper-
kalemia is most effective when severe acidosis is also present
[281 as in advanced uremia.
The ECG tracings revealed tenting of T-waves in seven
patients and additionally a pseudoinfarction pattern described
previously as a rare sign of hyperkalemia [29] in one of them.
After one hour of bicarbonate infusion, a single patient only
manifested improvement in tenting without a change in plasma
potassium, whereas hyperkalemic ECG changes improved or
disappeared in three more patients after six hours only. The
unchanged ECG in the majority of patients with alterations
induced by hyperkalemia after 60 minutes of therapy is an
additional argument for the inefficacy of bicarbonate as an
emergency treatment of hyperkalemia in patients with terminal
renal failure.
Considering hormonal factors involved in the homeostasis of
extracellular potassium, basal plasma aldosterone was ele-
vated, and aldosterone values correlated positively with potas-
sium levels in the present and in previously studied hemodial-
ysis patients [11, 30]. Basal plasma norepinephrine and
epinephrine also ranged from normal to elevated, as noted in
previous studies [11, 31, 32], while dopamine levels were
normal. The tendency of plasma aldosterone, norepinephrine
and epinephrine to decrease during the course of bicarbonate
infusion probably reflects in part the physiological diurnal
variation, and in part the increase in ECF volume. The decrease
in aldosterone is likely to have been promoted by the concom-
itant mild reduction in plasma potassium.
Plasma insulin levels were in the normal range over the entire
study period, which is in agreement with earlier studies by us
and by others [11, 31]. This is of some importance considering
the marked potassium lowering effect of intravenous insulin in
glucose [11]. Since alkalemia increases while acidemia dimin-
ishes the action of insulin, it seems possible that this effect
might have played a role in the observed mild decrease of
plasma potassium [33]. It is of note that one of the patients had
a borderline low blood glucose level and another was frankly
hypoglycemic, both without any clinical symptoms.
We conclude that in patients with terminal renal failure who
are maintained on hemodialysis and who have sufficient levels
of potassium regulating hormones, intravenous bicarbonate was
ineffective as a treatment of hyperkalemia for up to two hours;
after four and six hours it was accompanied by a modest fall in
plasma potassium which, however, was not quite reliable and
was obtained at the cost of a considerable sodium-volume load.
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